US business uncertainty and pricing erosion
US business remains a big unknown due to pricing erosion (~5% mid-single digit) and supply disruptions; management struggles to provide specific guidance.
high · management_commentary
Glenmark Pharmaceuticals Limited — Q2 FY24
Glenmark's Q2 FY24 consolidated revenue grew 6.3% YoY to INR 3,588 crore, driven by strong performance in Europe (+58.4%) and ROW (+19%), while India grew only 2.8% due to acute...
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Monroe facility reinspection timeline uncertain
Monroe facility remediation is largely complete, but FDA reinspection timeline is unpredictable, delaying potential revenue from the plant.
medium · analyst_questionGLS divestment execution risk
The GLS divestment to Nirma is subject to regulatory and shareholder approvals; any delay could impact FY25 margin and PAT improvement plans.
medium · management_commentaryIndia acute segment slowdown may persist
India business growth was impacted by slowdown in respiratory and dermatology; while October showed recovery, sustainability is uncertain.
low · data_observation